Acute Ischemic Stroke

Phase III trials of Cerovive initiated

Published in Pain and Central Nervous System Week, June 23rd, 2003

AstraZeneca (AZN) announced the initiation of two major phase III pivotal clinical trials to determine the effect of Cerovive (also known as NXY-059) on disability and neurological recovery in acute ischemic stroke patients.

The clinical trial program, known as the SAINT (Stroke - Acute Ischemic - NXY Treatment) Trials, will compare the efficacy and safety of a 72-hour intravenous infusion of Cerovive given within 6 hours of the onset of symptoms, versus placebo.

Two multinational, multicenter, double-blind, randomized, placebo-controlled parallel-group studies will be enrolling more than 3000 patients. The SAINT-I trial will involve 200 centers...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week

Source: Pain and Central Nervous System Week (2003-06-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry